X Yao1, T Corbett2, A A Gupta3, R A Kandel4, S Verma5, J Werier6, M Ghert7. 1. Cancer Care Ontario's Program in Evidence-Based Care, Department of Oncology, McMaster University, Hamilton, ON. 2. Division of Radiation Oncology, Juravinski Cancer Centre, Hamilton, ON. 3. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON. 4. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON. 5. Department of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON. 6. Department of Orthopaedic Surgery, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON. 7. Division of Orthopaedic Surgery, Juravinski.
Abstract
INTRODUCTION: We conducted a systematic review to determine the optimal treatment options in patients with desmoid tumours who have declined observational management. METHODS: A search was conducted of the medline and embase databases (1990 to September 2012), the Cochrane Library, and relevant guideline Web sites and conference materials. RESULTS: One systematic review and forty-six studies met the preplanned study selection criteria; data from twenty-eight articles were extracted and analyzed. For local control, three studies reported a statistically significant difference in favour of surgery plus radiotherapy (rt) compared with surgery alone, and one study did not; two studies reported the lack of a statistical difference between surgery plus rt and rt alone in maintaining local control. Multivariate risk factors for local recurrence included positive surgical margins and young patient age. Single-agent imatinib led to a progression-free survival rate of 55% at 2 years and 58% at 3 years. Methotrexate plus vinblastine led to a progression-free survival rate of 67% at 10 years. Significant toxicities were reported for all treatment modalities, including surgical morbidity, and rt- and chemotherapy-related toxicities. CONCLUSIONS: In patients who have declined observational management, the local control rate was higher with surgery plus rt than with surgery alone. However, the additional rt-related complications should be considered in treatment decision-making. Surgery, rt, and systemic therapy are all reasonable treatment options for patients with desmoid tumours.
INTRODUCTION: We conducted a systematic review to determine the optimal treatment options in patients with desmoid tumours who have declined observational management. METHODS: A search was conducted of the medline and embase databases (1990 to September 2012), the Cochrane Library, and relevant guideline Web sites and conference materials. RESULTS: One systematic review and forty-six studies met the preplanned study selection criteria; data from twenty-eight articles were extracted and analyzed. For local control, three studies reported a statistically significant difference in favour of surgery plus radiotherapy (rt) compared with surgery alone, and one study did not; two studies reported the lack of a statistical difference between surgery plus rt and rt alone in maintaining local control. Multivariate risk factors for local recurrence included positive surgical margins and young patient age. Single-agent imatinib led to a progression-free survival rate of 55% at 2 years and 58% at 3 years. Methotrexate plus vinblastine led to a progression-free survival rate of 67% at 10 years. Significant toxicities were reported for all treatment modalities, including surgical morbidity, and rt- and chemotherapy-related toxicities. CONCLUSIONS: In patients who have declined observational management, the local control rate was higher with surgery plus rt than with surgery alone. However, the additional rt-related complications should be considered in treatment decision-making. Surgery, rt, and systemic therapy are all reasonable treatment options for patients with desmoid tumours.
Authors: G Pignatti; G Barbanti-Bròdano; D Ferrari; F Gherlinzoni; F Bertoni; P Bacchini; E Barbieri; A Giunti; M Campanacci Journal: Clin Orthop Relat Res Date: 2000-06 Impact factor: 4.176
Authors: Brigitta G Baumert; Martin O Spahr; Arthur Von Hochstetter; Sylvie Beauvois; Christine Landmann; Katrin Fridrich; Salvador Villà; Michael J Kirschner; Guy Storme; Peter Thum; Hans K Streuli; Norbert Lombriser; Robert Maurer; Gerhard Ries; Ernst-Arnold Bleher; Alfred Willi; Juerg Allemann; Ulrich Buehler; Hugo Blessing; Urs M Luetolf; J Bernard Davis; Burkhardt Seifert; Manfred Infanger Journal: Radiat Oncol Date: 2007-03-07 Impact factor: 3.481
Authors: Kirsi Santti; Annette Beule; Laura Tuomikoski; Mikko Rönty; Anna-Stina Jääskeläinen; Kauko Saarilahti; Hanna Ihalainen; Maija Tarkkanen; Carl Blomqvist Journal: Strahlenther Onkol Date: 2017-01-02 Impact factor: 3.621
Authors: B Kasper; C Baumgarten; J Garcia; S Bonvalot; R Haas; F Haller; P Hohenberger; N Penel; C Messiou; W T van der Graaf; A Gronchi Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976